Market closedNon-fractional

SCYNEXIS/SCYX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About SCYNEXIS

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Ticker

SCYX

Sector

Healthcare

Trading on

NASDAQ

Industry

Pharmaceuticals

Headquarters

Jersey City, United States

Employees

29

SCYNEXIS Metrics

BasicAdvanced
$80M
Market cap
1.01
P/E ratio
$2.09
EPS
1.49
Beta
-
Dividend rate
$80M
1.49
3.718
3.646
3.356
20.557
14.69%
48.95%
458.59%
1.013
0.724
1.08
1.08
1.355
2,436.75%
-206.72%
126.70%
-17.13%

What the Analysts think about SCYNEXIS

Analyst Ratings

Majority rating from 5 analysts.
Buy

SCYNEXIS Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
30.76% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$1.3M
-77.19%
Net income
$400K
-102.05%
Profit margin
30.76%
-108.99%

SCYNEXIS Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 105.06%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$2.46
-$0.04
-$0.39
$0.01
-
Expected
$1.55
-$0.15
-$0.20
-$0.20
-$0.16
Surprise
58.91%
-72.60%
95.00%
-105.06%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for SCYNEXIS stock?

SCYNEXIS (SCYX) has a market cap of $80M as of July 23, 2024.

What is the P/E ratio for SCYNEXIS stock?

The price to earnings (P/E) ratio for SCYNEXIS (SCYX) stock is 1.01 as of July 23, 2024.

Does SCYNEXIS stock pay dividends?

No, SCYNEXIS (SCYX) stock does not pay dividends to its shareholders as of July 23, 2024.

When is the next SCYNEXIS dividend payment date?

SCYNEXIS (SCYX) stock does not pay dividends to its shareholders.

What is the beta indicator for SCYNEXIS?

SCYNEXIS (SCYX) has a beta rating of 1.49. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell SCYNEXIS stock

Buy or sell SCYNEXIS stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing